Quantitative microsampling for bioanalytical applications related to the SARS-CoV-2 pandemic: Usefulness, benefits and pitfalls

Protti, Michele; Mandrioli, Roberto; Mercolini, Laura

doi:10.1016/j.jpba.2020.113597

Cited by 27 publications

(19 citation statements)

References 114 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The use of dried blood spots (DBS), a collection method whereby capillary blood is collected onto filter paper, may facilitate more widespread testing by overcoming some of these obstacles [ 2 , 3 ]. Serological testing using DBS has already been validated and optimized for other viral infections including HIV and hepatitis B and C [ 4 , 5 , 6 , 7 , 8 , 9 , 10 , 11 , 12 , 13 , 14 , 15 ].…”

Section: Introductionmentioning

confidence: 99%

Evaluation of Dried Blood Spot Testing for SARS-CoV-2 Serology Using a Quantitative Commercial Assay

Brinc

Biondi

et al. 2021

Viruses

View full text Add to dashboard Cite

Dried blood spots (DBS) are commonly used for serologic testing for viruses and provide an alternative collection method when phlebotomy and/or conventional laboratory testing are not readily available. DBS collection could be used to facilitate widespread testing for SARS-CoV-2 antibodies to document past infection, vaccination, and potentially immunity. We investigated the characteristics of Roche’s Anti-SARS-CoV-2 (S) assay, a quantitative commercial assay for antibodies against the spike glycoprotein. Antibody levels were reduced relative to plasma following elution from DBS. Quantitative results from DBS samples were highly correlated with values from plasma (r2 = 0.98), allowing for extrapolation using DBS results to accurately estimate plasma antibody levels. High concordance between plasma and fingerpick DBS was observed in PCR-confirmed COVID-19 patients tested 90 days or more after the diagnosis (45/46 matched; 1/46 mismatched plasma vs. DBS). The assessment of antibody responses to SARS-CoV-2 using DBS may be feasible using a quantitative anti-S assay, although false negatives may rarely occur in those with very low antibody levels.

show abstract

Section: Introductionmentioning

confidence: 99%

Evaluation of Dried Blood Spot Testing for SARS-CoV-2 Serology Using a Quantitative Commercial Assay

Brinc

Biondi

et al. 2021

Viruses

View full text Add to dashboard Cite

show abstract

“…These findings are in line with similar studies [ 23–25 ]. Although DBS sampling does reduce sensitivity [ 8 , 26 ], our assay consistently demonstrated a similar level of sensitivity when the same samples were analyzed in serum. Care should be taken during sample collection, as sampling differences may affect overall DBS sample quality and introduce variability.…”

Section: Resultsmentioning

confidence: 71%

Validation of High-Throughput, Semiquantitative Solid-Phase Sarscoronavirus-2 Serology Assays in Serum and Dried Blood Spot Matrices

et al. 2021

View full text Add to dashboard Cite

Aim: Serological assays for the detection of anti-SARS coronavirus-2 (SARS-CoV-2) antibodies are essential to the response to the global pandemic. A ligand binding-based serological assay was validated for the semiquantitative detection of IgG, IgM, IgA and neutralizing antibodies (nAb) against SARS-CoV-2 in serum. Results: The assay demonstrated high levels of diagnostic specificity and sensitivity (85–99% for all analytes). Serum IgG, IgM, IgA and nAb correlated positively (R2 = 0.937, R2 = 0.839, R2 = 0.939 and R2 = 0.501, p < 0.001, respectively) with those measured in dried blood spot samples collected using the hemaPEN® microsampling device (Trajan Scientific and Medical, Victoria, Australia). In vitro SARS-CoV-2 pseudotype neutralization correlated positively with the solid phase nAb signals in convalescent donors (R2 = 0.458, p < 0.05). Conclusion: The assay is applicable in efficacy studies, infection monitoring and postmarketing surveillance following vaccine rollout.

show abstract

“…42,46,[80][81][82] The range of applications include therapeutic drugs, [83][84][85][86] biomarkers, 87,88 proteins and peptides, 89 drugs of abuse, 90,91 hormones and steroids, 92,93 DNA/RNA 56,87 and cytokines. 27,53,94 Few established applications discussed below focus on the use of microsampling techniques in the determination of drug concentration using a validated bioanalytical method.…”

Section: Applications Of Microsampling In the Development Of Treatmentsmentioning

confidence: 99%

Microsampling: A role to play in Covid‐19 diagnosis, surveillance, treatment and clinical trials

Rajadhyaksha

Londhe

2021

Drug Testing and Analysis

View full text Add to dashboard Cite

The outbreak of the new coronavirus disease changed the world upside down. Every day, millions of people were subjected to diagnostic testing for Covid‐19, all over the world. Molecular tests helped in the diagnosis of current infection by detecting the presence of viral genome whereas serological tests helped in detecting the presence of antibody in blood as well as contributed to vaccine development. This testing helped in understanding the immunogenicity, community prevalence, geographical spread and conditions post‐infection. However, with the contagious nature of the virus, biological specimen sampling involved the risk of transmission and spread of infection. Clinic or pathology visit was the most concerning part. Trained personnel and resources was another barrier. In this scenario, microsampling played an important role due to its most important advantage of remote, contactless, small volume and self‐sampling. Minimum requirements for sample storage and ease of shipment added value in this situation. The highly sensitive instruments and validated assay formats assured the accuracy of results and stability of samples. Microsampling techniques are contributing effectively to the Covid‐19 pandemic by reducing the demand for clinical staff in population‐level testing. The validated and established applications supported the use of microsampling in diagnosis, therapeutic drug monitoring, development of treatment or vaccines and clinical trials for Covid‐19.

show abstract

Quantitative microsampling for bioanalytical applications related to the SARS-CoV-2 pandemic: Usefulness, benefits and pitfalls

Abstract: Graphical abstract

Cited by 27 publications

References 114 publications

Evaluation of Dried Blood Spot Testing for SARS-CoV-2 Serology Using a Quantitative Commercial Assay

Evaluation of Dried Blood Spot Testing for SARS-CoV-2 Serology Using a Quantitative Commercial Assay

Validation of High-Throughput, Semiquantitative Solid-Phase Sarscoronavirus-2 Serology Assays in Serum and Dried Blood Spot Matrices

Microsampling: A role to play in Covid‐19 diagnosis, surveillance, treatment and clinical trials

Contact Info

Product

Resources

About